H.C. Wainwright Thinks Oncolytics Biotech’s Stock is Going to Recover

In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Oncolytics Biotech (ONCYResearch Report), with a price target of $15.00. The company’s shares closed last Thursday at $0.98, close to its 52-week low of $0.80.

According to TipRanks.com, Trucchio has 0 stars on 0-5 stars ranking scale with an average return of -16.1% and a 32.9% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oncolytics Biotech with a $15.00 average price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $2.60 and a one-year low of $0.80. Currently, Oncolytics Biotech has an average volume of 118.3K.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONCY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Read More on ONCY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed